Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Pharmanutra S.p.A. (PHN.MI)
Pisa, PI, IT
Pharmanutra S.p.A. functions as a pharmaceutical and nutraceutical enterprise, focusing on the research, development, design, and marketing of nutritional supplements and medical devices. Its market reach extends across Italy, other parts of Europe, the Middle East, the Far East, and globally. Moreover, the company manufactures and promotes pharmaceuticals, medical devices, over-the-counter (OTC) items, and nutraceuticals specifically for the pediatric population. Furthermore, Pharmanutra is a producer and supplier of raw materials and active ingredients to the food, pharmaceutical, and dietary supplement industries. Its diverse product portfolio features prominent brands like the SiderAL series (including SiderAL Forte, SiderAL Folic, Cardio SiderAL, SiderAL Med), the Cetilar range (Cetilar Crema, Cetilar Patch, Tape), along with ApportAL, UltraMag, Gestalys DHA, Novomega, Bonecal, and DiKappa 2. These products are distributed and sold through a network comprising sales representatives, wholesalers, pharmacies, and para-pharmacies. Established in 2003, the company's base of operations is in Pisa, Italy.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.11% | +4.53% | +10.16% | +33.93% | +77.87% | +66.98% | +73.08% | +56.79% | +143.90% | +543.32% | +543.32% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 3 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+13.4% ★ Q1'26: +22.4% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+20.8% ★ Q1'26: +44.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+10.9% Q1'26: +3.0% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+23.0% ★ Q1'26: +14.5% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+32.7% ★ Q1'26: +19.4% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-0.4% ★ Q1'26: -1.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.60× ★ Q1'26: 0.86× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 2 EPS Ana. |
Dec 2027 3 Rev. Ana. 2 EPS Ana. |
Dec 2028 3 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
37.78M
est: 39.40M (-4.1%)
|
46.67M
est: 43.20M (+8.0%)
|
53.81M
est: 53.00M (+1.5%)
|
58.48M
est: 56.85M (+2.9%)
|
68.14M
est: 67.83M (+0.5%)
|
83.39M
est: 83.03M (+0.4%)
|
101.03M
est: 107.61M (-6.1%)
|
116.15M
est: 116.33M (-0.2%)
|
131.69M
est: 132.37M (-0.5%)
|
154.59M
152.81M – 157.65M
+16.8% YoY
|
180.07M
175.03M – 189.22M
+16.5% YoY
|
203.73M
203.43M – 204.03M
+13.1% YoY
|
| EBITDA |
9.38M
est: 10.78M (-13.0%)
|
12.37M
est: 11.82M (+4.6%)
|
13.07M
est: 14.51M (-9.9%)
|
14.28M
est: 15.56M (-8.2%)
|
19.84M
est: 18.56M (+6.8%)
|
24.61M
est: 22.73M (+8.3%)
|
26.53M
est: 29.79M (-10.9%)
|
32.01M
est: 32.20M (-0.6%)
|
34.21M
est: 36.64M (-6.6%)
|
42.80M
42.30M – 43.64M
+16.8% YoY
|
49.85M
48.45M – 52.38M
+16.5% YoY
|
56.40M
56.32M – 56.48M
+13.1% YoY
|
| EBIT |
8.86M
est: 9.98M (-11.2%)
|
11.92M
est: 10.94M (+8.9%)
|
12.24M
est: 13.42M (-8.8%)
|
13.33M
est: 14.40M (-7.4%)
|
18.83M
est: 17.18M (+9.6%)
|
23.47M
est: 21.03M (+11.6%)
|
24.06M
est: 27.30M (-11.8%)
|
28.22M
est: 29.51M (-4.4%)
|
30.31M
est: 33.58M (-9.7%)
|
39.21M
38.76M – 39.99M
+16.8% YoY
|
45.68M
44.40M – 48.00M
+16.5% YoY
|
51.68M
51.60M – 51.76M
+13.1% YoY
|
| Net Income |
6.03M
est: 5.67M (+6.4%)
|
8.56M
est: 6.82M (+25.4%)
|
8.45M
est: 8.55M (-1.1%)
|
14.07M
est: 12.20M (+15.3%)
|
13.77M
est: 12.63M (+9.0%)
|
15.05M
est: 14.73M (+2.1%)
|
12.83M
est: 14.50M (-11.5%)
|
16.61M
est: 18.21M (-8.8%)
|
20.00M
est: 19.40M (+3.1%)
|
24.85M
24.43M – 24.89M
+28.1% YoY
|
30.79M
29.57M – 31.49M
+23.9% YoY
|
36.26M
34.28M – 37.60M
+17.8% YoY
|
| SGA |
11.86M
est: 12.99M (-8.7%)
|
21.54M
est: 14.25M (+51.2%)
|
24.87M
est: 17.48M (+42.3%)
|
24.08M
est: 18.75M (+28.5%)
|
26.13M
est: 22.37M (+16.8%)
|
31.17M
est: 27.38M (+13.8%)
|
22.55M
est: 26.90M (-16.2%)
|
29.80M
est: 29.08M (+2.5%)
|
1.68M
est: 33.09M (-94.9%)
|
38.64M
38.20M – 39.40M
+16.8% YoY
|
45.01M
43.75M – 47.30M
+16.5% YoY
|
50.92M
50.85M – 51.00M
+13.1% YoY
|
| EPS |
0.62
est: 0.59 (+5.1%)
|
0.88
est: 0.71 (+23.9%)
|
0.87
est: 0.89 (-2.2%)
|
1.45
est: 1.27 (+14.2%)
|
1.42
est: 1.31 (+8.0%)
|
1.56
est: 1.54 (+1.4%)
|
1.33
est: 1.50 (-11.6%)
|
1.73
est: 1.88 (-8.1%)
|
2.09
est: 2.01 (+4.2%)
|
2.58
2.55 – 2.60
+28.4% YoY
|
3.19
3.09 – 3.29
+23.8% YoY
|
3.76
3.58 – 3.93
+17.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-18 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-15 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-14 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-13 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-12 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-11 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-08 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-07 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-06 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-05 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-04 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-30 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | UBS MSCI EMU Small Cap UCITS ETF EUR dis UEFD.DE | 0.06% | 421.1K | 0.33% |
| 2 | Amundi MSCI EMU Small Cap ESG Broad Transition UCITS ETF Dist MMS.PA | 0.05% | 388.5K | 0.40% |
| 3 | iShares MSCI EMU Small Cap UCITS ETF CES1.L | 0.05% | 550.9K | 0.58% |
| 4 | iShares MSCI Europe Small-Cap ETF IEUS | 0.02% | 39.9K | 0.41% |
| 5 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Acc CEM.PA | 0.02% | 71.7K | 0.23% |
| 6 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Dist X026.DE | 0.02% | 71.7K | 0.23% |
| 7 | Xtrackers MSCI Europe Small Cap UCITS ETF 1C XXSC.L | 0.02% | 693.0K | 0.30% |
| 8 | Avantis International Small Cap Equity ETF AVDS | 0.02% | 50.2K | 0.30% |
| 9 | iShares Currency Hedged MSCI EAFE Small-Cap ETF HSCZ | 0.01% | 22.5K | 0.83% |
| 10 | iShares MSCI EAFE Small-Cap ETF SCZ | 0.01% | 1.35M | 0.40% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Andrea Lacorte | Founder, Chairman & Executive Director | 3M | male |
| Roberto Lacorte | Co-Founder, MD, Vice Chairman & Executive Director | 2M | male |
| Carlo Volpi | Delegate Advisor, Chief Operating Officer & Executive Director | 2M | male |
| Germano Tarantino | Scientific Director & Executive Director | 667.0K | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PHN.MI
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
